Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE.

J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w.

2.

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M.

J Immunother Cancer. 2019 Nov 18;7(1):309. doi: 10.1186/s40425-019-0769-8.

3.

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, Guillaume P, Coukos G, Harari A, Jandus C, Bassani-Sternberg M, Gfeller D.

Nat Biotechnol. 2019 Nov;37(11):1283-1286. doi: 10.1038/s41587-019-0289-6. Epub 2019 Oct 14.

PMID:
31611696
4.

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.

Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson BJ, Thierry AC, Michaux J, Pak H, Racle J, Boudousquie C, Balint K, Coukos G, Gfeller D, Martin Lluesma S, Harari A, Demartines N, Kandalaft LE.

Front Immunol. 2019 Aug 8;10:1832. doi: 10.3389/fimmu.2019.01832. eCollection 2019.

5.

Comment on "A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands".

Rolfs Z, Müller M, Shortreed MR, Smith LM, Bassani-Sternberg M.

Sci Immunol. 2019 Aug 16;4(38). pii: eaaw1622. doi: 10.1126/sciimmunol.aaw1622.

PMID:
31420320
6.

Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Ebrahimi-Nik H, Michaux J, Corwin WL, Keller GL, Shcheglova T, Pak H, Coukos G, Baker BM, Mandoiu II, Bassani-Sternberg M, Srivastava PK.

JCI Insight. 2019 Jun 20;5. pii: 129152. doi: 10.1172/jci.insight.129152.

7.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Apr;120(8):870. doi: 10.1038/s41416-019-0425-6.

8.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Feb;120(4):424-434. doi: 10.1038/s41416-019-0384-y. Epub 2019 Feb 5. Erratum in: Br J Cancer. 2019 Apr;120(8):870.

PMID:
30718808
9.

High-Throughput, Fast, and Sensitive Immunopeptidomics Sample Processing for Mass Spectrometry.

Marino F, Chong C, Michaux J, Bassani-Sternberg M.

Methods Mol Biol. 2019;1913:67-79. doi: 10.1007/978-1-4939-8979-9_5.

PMID:
30666599
10.

The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M.

J Immunol. 2018 Dec 15;201(12):3705-3716. doi: 10.4049/jimmunol.1800914. Epub 2018 Nov 14.

PMID:
30429286
11.

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.

Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M.

Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.

12.

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.

Mylonas R, Beer I, Iseli C, Chong C, Pak HS, Gfeller D, Coukos G, Xenarios I, Müller M, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Dec;17(12):2347-2357. doi: 10.1074/mcp.RA118.000877. Epub 2018 Aug 31.

13.

Predicting Antigen Presentation-What Could We Learn From a Million Peptides?

Gfeller D, Bassani-Sternberg M.

Front Immunol. 2018 Jul 25;9:1716. doi: 10.3389/fimmu.2018.01716. eCollection 2018. Review.

14.

Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE).

Lill JR, van Veelen PA, Tenzer S, Admon A, Caron E, Elias JE, Heck AJR, Marcilla M, Marino F, Müller M, Peters B, Purcell A, Sette A, Sturm T, Ternette N, Vizcaíno JA, Bassani-Sternberg M.

Proteomics. 2018 Jun;18(12):e1800110. doi: 10.1002/pmic.201800110.

15.

The C-terminal extension landscape of naturally presented HLA-I ligands.

Guillaume P, Picaud S, Baumgaertner P, Montandon N, Schmidt J, Speiser DE, Coukos G, Bassani-Sternberg M, Filippakopoulos P, Gfeller D.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5083-5088. doi: 10.1073/pnas.1717277115. Epub 2018 Apr 30.

16.

Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.

Bassani-Sternberg M.

Methods Mol Biol. 2018;1719:209-221. doi: 10.1007/978-1-4939-7537-2_14.

PMID:
29476514
17.

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.

Chong C, Marino F, Pak H, Racle J, Daniel RT, Müller M, Gfeller D, Coukos G, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Mar;17(3):533-548. doi: 10.1074/mcp.TIR117.000383. Epub 2017 Dec 14.

18.

'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.

Müller M, Gfeller D, Coukos G, Bassani-Sternberg M.

Front Immunol. 2017 Oct 20;8:1367. doi: 10.3389/fimmu.2017.01367. eCollection 2017.

19.

The SysteMHC Atlas project.

Shao W, Pedrioli PGA, Wolski W, Scurtescu C, Schmid E, Vizcaíno JA, Courcelles M, Schuster H, Kowalewski D, Marino F, Arlehamn CSL, Vaughan K, Peters B, Sette A, Ottenhoff THM, Meijgaarden KE, Nieuwenhuizen N, Kaufmann SHE, Schlapbach R, Castle JC, Nesvizhskii AI, Nielsen M, Deutsch EW, Campbell DS, Moritz RL, Zubarev RA, Ytterberg AJ, Purcell AW, Marcilla M, Paradela A, Wang Q, Costello CE, Ternette N, van Veelen PA, van Els CACM, Heck AJR, de Souza GA, Sollid LM, Admon A, Stevanovic S, Rammensee HG, Thibault P, Perreault C, Bassani-Sternberg M, Aebersold R, Caron E.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1237-D1247. doi: 10.1093/nar/gkx664.

20.

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D.

PLoS Comput Biol. 2017 Aug 23;13(8):e1005725. doi: 10.1371/journal.pcbi.1005725. eCollection 2017 Aug.

21.

A Case for a Human Immuno-Peptidome Project Consortium.

Caron E, Aebersold R, Banaei-Esfahani A, Chong C, Bassani-Sternberg M.

Immunity. 2017 Aug 15;47(2):203-208. doi: 10.1016/j.immuni.2017.07.010.

22.

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM.

Nat Commun. 2016 Nov 21;7:13404. doi: 10.1038/ncomms13404.

23.

Current tools for predicting cancer-specific T cell immunity.

Gfeller D, Bassani-Sternberg M, Schmidt J, Luescher IF.

Oncoimmunology. 2016 Apr 25;5(7):e1177691. doi: 10.1080/2162402X.2016.1177691. eCollection 2016 Jul. Review.

24.

Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions.

Bassani-Sternberg M, Gfeller D.

J Immunol. 2016 Sep 15;197(6):2492-9. doi: 10.4049/jimmunol.1600808. Epub 2016 Aug 10.

25.

Mass spectrometry-based antigen discovery for cancer immunotherapy.

Bassani-Sternberg M, Coukos G.

Curr Opin Immunol. 2016 Aug;41:9-17. doi: 10.1016/j.coi.2016.04.005. Epub 2016 May 4. Review.

PMID:
27155075
26.

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.

Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.

Gastroenterology. 2015 Oct;149(4):1042-52. doi: 10.1053/j.gastro.2015.05.055. Epub 2015 Jun 5.

PMID:
26052074
27.

Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.

Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M.

Mol Cell Proteomics. 2015 Mar;14(3):658-73. doi: 10.1074/mcp.M114.042812. Epub 2015 Jan 9.

28.

The Human Immunopeptidome Project, a suggestion for yet another postgenome next big thing.

Admon A, Bassani-Sternberg M.

Mol Cell Proteomics. 2011 Oct;10(10):O111.011833. doi: 10.1074/mcp.O111.011833. Epub 2011 Aug 2.

29.

Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Bassani-Sternberg M, Barnea E, Beer I, Avivi I, Katz T, Admon A.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18769-76. doi: 10.1073/pnas.1008501107. Epub 2010 Oct 25.

Supplemental Content

Loading ...
Support Center